U.S. Markets closed

Gilead's stock is up about 4% after sharing new data for cancer drug

·1 min read
Gilead's stock is up about 4% after sharing new data for cancer drug

Shares of Gilead Sciences Inc. were up 4.9% in trading on Monday after the company said in a news release that Trodelvy improved overall survival rates in people with HR+/HER2- metastatic breast cancer. Gilead said it already filed an application with the Food and Drug Administration asking the regulator to approve the Trodelvy for this group of patients. It also said it expects to soon share full data from this clinical trial, which will help Wall Street analysts understand how Trodelvy will co